Hutchmed Limited Stock Performance
| HMDCF Stock | USD 3.66 0.00 0.00% |
On a scale of 0 to 100, HUTCHMED (China) holds a performance score of 10. The company retains a Market Volatility (i.e., Beta) of 0.0109, which attests to not very significant fluctuations relative to the market. As returns on the market increase, HUTCHMED (China)'s returns are expected to increase less than the market. However, during the bear market, the loss of holding HUTCHMED (China) is expected to be smaller as well. Please check HUTCHMED (China)'s information ratio, and the relationship between the coefficient of variation and skewness , to make a quick decision on whether HUTCHMED (China)'s current trending patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in HUTCHMED Limited are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile fundamental indicators, HUTCHMED (China) reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 235.6 M | |
| Total Cashflows From Investing Activities | -306.3 M |
HUTCHMED |
HUTCHMED (China) Relative Risk vs. Return Landscape
If you would invest 321.00 in HUTCHMED Limited on September 26, 2025 and sell it today you would earn a total of 45.00 from holding HUTCHMED Limited or generate 14.02% return on investment over 90 days. HUTCHMED Limited is currently producing 0.2225% returns and takes up 1.7662% volatility of returns over 90 trading days. Put another way, 15% of traded pink sheets are less volatile than HUTCHMED, and 96% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
HUTCHMED (China) Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for HUTCHMED (China)'s investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as HUTCHMED Limited, and traders can use it to determine the average amount a HUTCHMED (China)'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.126
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HMDCF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average HUTCHMED (China) is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of HUTCHMED (China) by adding it to a well-diversified portfolio.
HUTCHMED (China) Fundamentals Growth
HUTCHMED Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of HUTCHMED (China), and HUTCHMED (China) fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on HUTCHMED Pink Sheet performance.
| Return On Equity | -0.25 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (0.64) % | |||
| Operating Margin | (0.95) % | |||
| Current Valuation | 1.66 B | |||
| Shares Outstanding | 864.77 M | |||
| Price To Book | 3.03 X | |||
| Price To Sales | 6.53 X | |||
| Revenue | 356.13 M | |||
| EBITDA | (207.96 M) | |||
| Cash And Equivalents | 829.71 M | |||
| Cash Per Share | 0.98 X | |||
| Book Value Per Share | 0.95 X | |||
| Cash Flow From Operations | (204.22 M) | |||
| Total Asset | 1.37 B | |||
About HUTCHMED (China) Performance
By analyzing HUTCHMED (China)'s fundamental ratios, stakeholders can gain valuable insights into HUTCHMED (China)'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if HUTCHMED (China) has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if HUTCHMED (China) has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
HUTCHMED Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 2110 people.Things to note about HUTCHMED Limited performance evaluation
Checking the ongoing alerts about HUTCHMED (China) for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for HUTCHMED Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| HUTCHMED Limited has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 356.13 M. Net Loss for the year was (194.65 M) with loss before overhead, payroll, taxes, and interest of (201.19 M). | |
| HUTCHMED Limited has accumulated about 829.71 M in cash with (204.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.98. | |
| Roughly 45.0% of the company shares are held by company insiders |
- Analyzing HUTCHMED (China)'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether HUTCHMED (China)'s stock is overvalued or undervalued compared to its peers.
- Examining HUTCHMED (China)'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating HUTCHMED (China)'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of HUTCHMED (China)'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of HUTCHMED (China)'s pink sheet. These opinions can provide insight into HUTCHMED (China)'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for HUTCHMED Pink Sheet analysis
When running HUTCHMED (China)'s price analysis, check to measure HUTCHMED (China)'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HUTCHMED (China) is operating at the current time. Most of HUTCHMED (China)'s value examination focuses on studying past and present price action to predict the probability of HUTCHMED (China)'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HUTCHMED (China)'s price. Additionally, you may evaluate how the addition of HUTCHMED (China) to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |